Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Rapid Micro Biosystems Inc(RPID)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for RPID
10/23/2026: RPID (1-star) is currently NOT-A-BUY. Pass it for now.
Rapid Micro Biosystems is a life sciences company providing automated microbial detection platforms for pharmaceutical manufacturing. The company's strengths include a proprietary, high-value technology and a recurring revenue model from consumables. Its growth story centers on replacing manual quality control processes with automated systems to improve pharmaceutical manufacturing safety. Risks are primarily related to its ongoing operating losses, long customer sales cycles, and competition from large, established life science providers. It is generally suited for growth-oriented investors who monitor the company's installed base expansion and its path toward profitability as key performance developments.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company provides a disruptive technology in a regulated market, but growth has been inconsistent. |
| Momentum investor | Weak fit | The stock has not shown sustained price appreciation required for a momentum strategy. |
| Value investor | Weak fit | The company is not currently profitable, making traditional value metrics difficult to apply. |
| Dividend investor | Weak fit | The company does not pay dividends. |
| Low-risk investor | Weak fit | High volatility and operational losses make this a high-risk equity. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock price is subject to significant fluctuations due to the small-cap nature and speculative growth phase. |
| Valuation risk | Medium / high | Valuation remains sensitive to growth expectations and interest rate environments. |
| Competition risk (Instrumentation and Microbiology) | High | Large competitors with established relationships can outspend or bundle competing solutions. |
| Business quality | Medium | The business model has potential for high-quality recurring revenue, but the path to scale and profitability is uncertain. |
| Dividend income | Low / none | There is no dividend payout. |
| Execution risk | High | Successfully expanding the installed base and managing operating costs is critical to long-term viability. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Highly Choppy
The stock has experienced frequent, large price swings that make its near-term movement less predictable.
Analysis of Past Performance
Type Stock | Historic Profit -31.63% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/23/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 39.12M USD | Price to earnings Ratio - | 1Y Target Price 5.75 |
Price to earnings Ratio - | 1Y Target Price 5.75 | ||
Volume (30-day avg) 271.2K shares | Beta 1.5 | 52 Weeks Range 0.76 - 4.94 | Updated Date 10/24/2026 |
52 Weeks Range 0.76 - 4.94 | Updated Date 10/24/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.11 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Product Sales | Direct sales and leasing of Growth Direct automated microbial detection instruments. | Revenue from the initial sale or placement of the machines used by pharmaceutical companies. |
| Consumables | Proprietary test kits and reagents required to run the Growth Direct system. | Recurring income similar to a printer cartridge model, which increases as more machines are used. |
| Services | Installation, validation, training, and maintenance support. | Steady service revenue generated from supporting the systems currently in use. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 63.90M | Price to Sales(TTM) 1.11 |
Enterprise Value 63.90M | Price to Sales(TTM) 1.11 | ||
Enterprise Value to Revenue 1.79 | Enterprise Value to EBITDA 0.82 | Shares Outstanding 45.66M | Shares Floating 23.91M |
Shares Outstanding 45.66M | Shares Floating 23.91M | ||
Percent Insiders 10.11 | Percent Institutions 46.69 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.